Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) under the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding internal plan transactions rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the GSK 401K plan. This resulted in an increase in the notional allocation of American Depositary Shares (ADSs) on November 22, 2013, at a price of $53.36 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Type: Increase in notional ADS allocation within the GSK 401K plan due to revaluation.
- Involved Parties: Dr. M. Slaoui (Director) and Dr. K. Slaoui (Connected Person).
- Transaction Volume: 4 ADSs.
- Transaction Price: $53.36 per ADS.
- Transaction Date: November 22, 2013.
- Notification Date: November 25, 2013.